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Abstract
Suppose one wishes to estimate the effect of a binary treatment on a binary endpoint
conditional on a (possibly continuous) post-randomization quantity in a counterfactual
world where all subjects received treatment. It is generally difficult to identify this pa-
rameter without strong, untestable assumptions. It has been shown that identifiability
assumptions become much weaker under a crossover design where (some subset of)
subjects not receiving treatment are later given treatment. Under the assumption
that the post-treatment biomarker observed in these crossover subjects is the same as
would have been observed had they received treatment at the start of the study, one
can identify the treatment effect with only mild additional assumptions. This remains
true if the endpoint is absorbent, i.e. an endpoint such as death or HIV infection
such that the post-crossover treatment biomarker is not meaningful if the endpoint
has already occurred. In this work, we review identifiability results for a parameter
of the distribution of the data observed under a crossover design with the principally
stratified treatment effect of interest. We describe situations where these assumptions
would be falsifiable given a sufficiently large sample from the observed data distribu-
tion, and show that these assumptions are not otherwise falsifiable. We then provide a
targeted minimum loss-based estimator for the setting that makes no assumptions on
the distribution that generated the data. When the semiparametric efficiency bound is
well defined, for which the primary condition is that the biomarker is discrete-valued,
this estimator is efficient among all regular and asymptotically linear estimators and
is more efficient than existing nonparametric approaches in situations where a contin-
uous baseline covariate is predictive of either the outcome or the biomarker. We also
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present a version of this estimator for situations where the biomarker is continuous.
Implications to closeout designs for vaccine trials are discussed.
Keywords: absorbent binary endpoints; closeout design; crossover design; principal stratifi-
cation
1 Introduction
Suppose one wishes to assess the effect of a binary treatment on a binary endpoint. For
simplicity, we refer to the levels of the treatment as “treated” and “untreated”, but one
could alternatively study a contrast between two active treatments. The objective is to
develop a biomarker that explains much of the treatment effect variation, i.e. a variable
for which the stratified treatment effect is highly variable. Sometimes, the most predictive
biomarkers are defined using the counterfactual values that a post-treatment biomarker
would take had a subject been treated or untreated. Conditioning on these biomarkers was
termed principal stratification by Frangakis and Rubin (2002). Principally stratified analyses
are especially interesting in situations where one wishes to bridge a treatment’s efficacy from
one population to another, and so treats a small subset of the new population and observes
their biomarkers in order to predict what the treatment effect would be in this population
(Gilbert et al., 2011). Though additional transportability assumptions (Bareinboim and
Pearl, 2012) are needed to be able to bridge a treatment effect, these assumptions become
more plausible if a strong effect modifier is available. In this paper, we focus only on
counterfactual post-randomization biomarkers that occur under treatment. This ensures
that one could observe the counterfactual biomarker under an appropriate intervention –
this is in contrast to stratifying on the biomarker’s counterfactual value both after treatment
and after a lack of treatment. Furthermore, in vaccine studies, which represent an important
application area, the post-treatment biomarkers of most interest are immune responses, and
in many settings untreated subjects who have not experienced the endpoint will have no
immune response, so that studying treatment effects conditional on unvaccinated immune
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responses is uninteresting. We assume that the endpoint is absorbent (Nason and Follmann,
2010), so that the biomarker has no substantive meaning once the endpoint has occurred. For
example, if the treatment is vaccination, the biomarker is vaccine-induced immune response,
and the endpoint is HIV infection, then a measured immune response is only of interest if it
precedes HIV infection. For most biomarkers of interest, death is also an absorbent endpoint.
Under most study designs, identifying principally stratified treatment effects requires
strong, untestable assumptions. In the context of vaccine trials, Follmann (2006) demon-
strated the utility of crossover designs (e.g., Woods et al., 1989) for dramatically weakening
these needed assumptions, where here the designs were referred to as closeout placebo vac-
cination designs and featured a crossover of uninfected placebos to the vaccine. There have
since been numerous works that study closeout designs (Gilbert and Hudgens, 2008; Wolfson
and Gilbert, 2010; Gabriel and Gilbert, 2013; Huang et al., 2013). Others have demonstrated
that crossover designs are also of interest for estimating principally stratified treatment ef-
fects for treatments other than vaccines (Wolfson and Henn, 2014; Gabriel and Follmann,
2016). All of these earlier works either relied on baseline covariates being discrete or on
correctly specified (semi)parametric models. In this work, we provide an estimator of prin-
cipally stratified treatment effects that is efficient within the nonparametric model that at
most makes assumptions on the probability of receiving treatment given covariates. The
efficiency of this estimator relies on the biomarker being discrete, since otherwise the semi-
parametric efficiency bound (Pfanzagl, 1990; Bickel et al., 1993) will not be defined. We
then generalize this nonparametric estimator to the case that the biomarker is continuous.
From a practical standpoint, closeout placebo vaccinations are easy to perform in a
vaccine clinical trial setting because uninfected placebo recipients are still under follow-up
at the end of the trial and are thus able to be vaccinated. Nonetheless, a downside to
performing a vaccinating uninfected placebo recipients at the end of the study is that they
are no longer available for additional follow-up as placebo recipients, making it difficult to
assess the long-term efficacy of the vaccine. One option is to only vaccinate a (random)
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subset of uninfected placebo recipients at the end of a trial so that some placebo recipients
are still available for longer-term follow-up.
We note that studying principally stratified treatment effects answers fundamentally
different questions than does studying direct effects (Robins and Greenland, 1992; Pearl,
2001; VanderWeele, 2015), which would aim to study the effect of treatment on the outcome
if the post-treatment biomarker were set to some fixed value or to the value it would have
taken had the subject been untreated. This is in contrast to principal stratification analyses,
which are useful for bridging vaccine efficacy from one population to another, provided one
collects the post-treatment biomarker on a small subset of subjects in the new population and
certain transportability assumptions hold. Identifying counterfactual direct effect estimands
with the observed data distribution requires strong assumptions, including that there are no
unmeasured confounders of the effect of the biomarker on the outcome (Cole and Herna´n,
2002). In crossover studies, this no-unmeasured-confounders assumption does not need to
hold to obtain valid inference for the principally stratified parameters that we study in this
work. Nonetheless, we emphasize that estimation should be focused on the quantity that
best reflects the scientific question. Furthermore, we note that, though principally stratified
analyses focus on a different quantity than direct effect analyses, it has been shown that the
presence of a nonzero principally stratified effect, conditional equality of the counterfactual
biomarker under treatment and the counterfactual biomarker under a lack of treatment,
implies the presence of a nonzero direct effect (VanderWeele, 2008); the reverse implication
does not hold. In this work, we study effects stratified only on the counterfactual biomarker
under treatment, so the result of VanderWeele (2008) does not generally apply. Nonetheless,
in settings in which the counterfactual biomarker under a lack of treatment is degenerate at
some value s0, e.g. in HIV vaccine studies where the biomarker is an immune response and
there is no immune response if the vaccine is not administered, the presence of a nonzero
treatment effect conditional on the counterfactual biomarker value under treatment equal
to s0 indicates the presence of a direct effect, i.e. an effect in a counterfactual world where
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treatment was administered and the biomarker had been set to s0.
Organization of Manuscript. Section 2 introduces the notation, parameters of the coun-
terfactual distribution, identifiability of these parameters with parameters of the observed
data distribution, and the statistical estimation problem. Section 3 describes our proposed
estimator when the biomarker is discrete. Section 4 presents an extension of this estimation
scheme to two-phase sampling studies. Section 5 presents an estimator that can be used
when the biomarker is continuous. For simplicity, this estimator is presented in a single-
phase sampling setup, but the extension to two-phase sampling is straightforward. Section 6
presents a simulation study. Section 7 closes with a discussion.
Appendix A provides proofs of the results from the main text. Appendix B presents
theorems and proofs for the validity of the estimator for continuous biomarkers presented in
Section 5. Appendix C gives a brief review of the derivation of efficient influence functions,
which are used to define our estimators. Appendix D presents a TMLE that can be used
when the data was derived from a two-phase sampling design. Appendix E gives additional
simulation results.
2 Notation and Identifiability
Consider the counterfactual data structure (W,A, S1, Y0, Y1, S
c
0) drawn from a distribution
P F , where W is a baseline covariate, A is a treatment indicator, S1 is a post-treatment
biomarker, Ya is a counterfactual outcome of interest under treatment a that takes on values
zero and one, and Sc0 is the counterfactual post-crossover biomarker had the subject not been
treated at baseline and subsequently been crossed over to treatment. In a closeout placebo
vaccination study, S1 represents a post-vaccination immune response, and S
c
0 denotes the
closeout biomarker measurements for placebos with Y = 0, and Sc0 = 0 for all other subjects.
To simplify presentation, we assume that S1 and S
c
0 are measured immediately following
treatment. One could alternatively assume that no events occur before the time at which
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S1 is measured (Follmann, 2006), or could assume some form of equal clinical risk, which
roughly states that the risk of the event occurring before this time point is equal between
treated and untreated subjects (Wolfson and Gilbert, 2010).
The objective is to estimate a contrast between the principally stratified mean outcome on
treatment and in the absence of treatment, i.e. between EF [Y1|S1 = s?1] and EF [Y0|S1 = s?1],
where here and throughout we let EF denote an expectation under P F and we define s?1 as
a particularly interesting value of the biomarker S1. For example, we may be interested in
estimating the principally stratified relative risk
RRF (s?1) ≡
EF [Y1|S1 = s?1]
EF [Y0|S1 = s?1]
or vaccine efficacy
VEF (s∗1) ≡ 1−
EF [Y1|S1 = s?1]
EF [Y0|S1 = s?1]
(1)
One may also be interested in RRF or VEF as a curve, across all values of s?1. The devel-
opments in this work can also be used to estimate an additive contrast, thereby giving the
conditional additive treatment effect.
In practice, we observe (W,A, S, Y, Sc) ∼ P . We wish to identify the principally stratified
mean outcomes with a parameter of this observed data distribution P . We make the following
identifiability assumptions, where we note that here and throughout we use E to denote an
expectation under P :
(A1) A draw of O = (W,A, S, Y, Sc) from P has the same distribution as a draw of
(W,A,1A=1 S1, YA,1A=0 S
c
0) from P
F .
The above is implied by the consistency assumption, which states that S1 = S if A = 1,
Y = YA, and S
c = Sc0 if A = 0. We also make the following assumptions:
(A2) Ignorable treatment assignment: A ⊥ (S1, Y0, Y1)|W , and
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(A3) Crossover assumption: for P F almost all w, S1|Y0 = 0,W = w under P F has the same
distribution as Sc0|Y0 = 0,W = w under P F .
This assumption is ill-defined when P F (Y0 = 0|W = w) = 0, but we note that it could
be replaced by equality of the conditional subdistribution functions S1, Y0 = 0|W = w and
Sc0, Y0 = 0|W = w under P F . If only the effect at a single s?1 is of interest, then the final
assumption above could be replaced by the weaker assumption that, for P F almost all w,
P F (S1 = s
?
1|Y0 = 0,W = w) = P F (Sc0 = s?1|Y0 = 0,W = w). Note that, in either case, the
third assumption above is implied by Sc0 = S1 almost surely, but does not require this. As
an example of the greater generality of the above assumption, it allows for a true underlying
biomarker to be measured with error, where the conditional probability statement is then
interpreted for the noised measurement of the underlying biomarker. Note also that this
assumption becomes weaker as the baseline covariate W become more predictive of S1 and
Sc0. Therefore, using the richest possible baseline covariate by including all available subject-
level information is expected to yield the most plausible crossover assumption.
Throughout we also require the strong positivity assumption that, for some δ > 0, the
treatment mechanism P (A = 1|W ) falls between δ and 1 − δ with probability one over
W ∼ P . We will also assume that there exists some fixed δ > 0 so that any estimate of the
treatment mechanism discussed in this paper satisfies the strong positivity assumption with
probability approaching one. In Appendix A.1, we prove the following identifiability result.
Theorem 1. If A1, A2, and A3 hold, then:
1. P F (S1 = s
?
1) = E[P (S = s?1|A = 1,W )],
2. P F (Y1 = 1, S1 = s
?
1) = E [P (Y = 1, S = s?1|A = 1,W )], and
3. P F (Y0 = 0, S1 = s
?
1) = E [P (Y = 0, Sc = s?1|A = 0,W )].
These identifiability results enable the identification of P F (Y1 = 1|S1 = s?1) = P
F (Y1=1,S1=s?1)
PF (S1=s?1)
and of P F (Y0 = 1|S1 = s?1) = 1− P
F (Y0=0,S1=s?1)
PF (S1=s?1)
, and therefore also enable the identification
of the principally stratified relative risk or any other contrast of these two quantities.
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It will be convenient to define parameters mapping from our statistical modelM, i.e. the
nonparametric model that at most places restrictions on the probability of receiving treat-
ment A = 1 given covariates W , to the real line. In particular, for an arbitrary distribution
P ′ ∈ M, we define parameters corresponding to each of the above identifiability results,
where to ease notation we omit the dependence of these parameters on the choice of s?1:
1. Ψ1(P
′) ≡ EP ′ [P ′(S = s?1|A = 1,W )],
2. Ψ2(P
′) ≡ EP ′ [EP ′ [Y |A = 1, S = s?1,W ]P ′(S = s?1|A = 1,W )], and
3. Ψ3(P
′) ≡ EP ′ [P ′ (Sc = s?1|A = 0, Y = 0,W )P ′(Y = 0|A = 0,W )].
Note that, under our identifiability conditions, the principally stratified relative risk is equal
to
RRP (s?1) ≡
Ψ2(P
′)
Ψ1(P ′)−Ψ3(P ′) . (2)
While the numerator above is bounded between 0 and 1, the denominator may be negative.
Therefore, it is possible that the above, which is supposedly identified with a counterfactual
relative risk, is negative. This is of course impossible, and therefore indicates a failure of our
identifiability assumptions. In Theorem A.1 of Appendix A.1.2 we show that, under A1 and
A2, the assumption A3 is not falsifiable from the observed data distribution if Ψ4(P ) = 0,
where
Ψ4(P
′) ≡
∫ ∫ (
P ′ (Sc = s1, Y = 0|A = 0, w)− P ′(S = s1|A = 1, w)
)+
dP ′(S = s1|A = 1, w)dP ′(w).
Above x+ denotes the positive part of x. If, on the other hand, A1 and A2 hold and
ΨF4 (P
F ) > 0, then it is easy to show that A3 cannot hold. Our statistical inference for the
principally stratified relative risk will hinge on A3. The fact that Ψ4(P ) > 0 implies that
A3 is false suggests that one could provide a test of A3, and perform this test as a sanity
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check before proceeding with inference for the principally stratified relative risk. We do not
further consider such a test here.
3 Estimation for discrete biomarker
Until otherwise stated, we work at fixed s?1. Suppose we observe n i.i.d. samples O1, . . . , On ∼
P , where Oi = (Wi, Ai, Si, Yi, S
c
i ). The notational overload on subscripts (indexing subject
i and counterfactuals) will not be problematic because the remainder of this work focuses
only on observed data quantities.
We will present an estimator of Ψ(P ) ≡ (Ψk(P ) : k = 1, 2, 3) ≡ (ψk : k = 1, 2, 3) and
show that it has a normal limiting distribution. This will enable both a test of A3 and
the construction of confidence intervals for the quantity RRP (s?1) that is, under conditions
discussed in the previous section, identified with the principally stratified relative risk. Before
the presentation of this estimator, whose construction is somewhat involved, Section 3.1
motivates the theoretical development needed to define the estimator. Section 3.2 presents
the estimator.
3.1 Motivation
We will derive the efficient influence function DP
′
: O → R3 of the parameter Ψ, where we
note that, as the notation suggests, the influence function depends on the distribution P ′ at
which Ψ is evaluated. While a more thorough review of the definition of efficient influence
functions is given in Appendix C, the key result is that they yield a first-order expansion of
the form:
Ψ(P ′)−Ψ(P ) = −EP
[
DP
′
(O)
]
+ Rem(P, P ′), (3)
where above Rem(P, P ′) ∈ R3 is small (in Euclidean norm) relative to the leading term on
the right whenever P ′ is close to P . In our setting, P ′ will denote an estimate of P , where
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one really only needs to estimate the conditional expectations and probabilities under P
needed to evaluate Ψ and D, rather than the entire distribution. Once this result has been
established, we will use it to develop a targeted minimum loss-based estimator (TMLE)
of the three-dimensional estimand ψ. We can then estimate any smooth function of this
quantity, e.g. a relative risk.
Before presenting the TMLE, which is somewhat complex, we provide intuition as to its
strong theoretical properties. Suppose we have estimated the components of P needed to
evaluate Ψ and D. Denote the estimate by Pˆ . Further suppose that this initial estimate is
close to P in the sense that Rem(P, Pˆ ) ≈ 0, where we later give an explicit expression for
this remainder and also give an exact rate requirement to make the approximation symbol
precise. Then, by (3), one has that Ψ(Pˆ )−Ψ(P ) ≈ −EP [DPˆ (O)]. Because DP is mean zero
when applied to draws of O ∼ P , if Pˆ is close to the true data generating distribution then
it is expected that the right-hand side is close to zero. Nonetheless, when W is continuous
it is difficult to quantify how close to zero this expectation is. The TMLE overcomes this
challenge by obtaining an estimate Pˆ ∗ that is a slight fluctuation of Pˆ , where this fluctuated
estimate now satisfies
1
n
n∑
i=1
DPˆ
∗
(Oi) = 0. (4)
In fact, it would suffice for the left-hand side to converge to zero in probability faster than
the inverse of the square root of the sample size. Arguments from M-estimation can be
used to show that the fluctuation step does not destroy the convergence properties of the
initial estimate Pˆ , so that Rem(P, Pˆ ∗) ≈ 0 whenever this statement holds for the initial,
unfluctuated estimator. Combining the above with (3), we have that
Ψ(Pˆ ∗)−Ψ(P ) ≈ 1
n
n∑
i=1
{
DPˆ
∗
(Oi)− EP
[
DPˆ
∗
(O)
]}
.
Multiplying both sides by the square root of sample size, and noting that, under some minor
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regularity conditions, DPˆ
∗
can be replaced by its mean-square limit (often, though not al-
ways, this will be DP ), we obtain the convergence in distribution result n1/2 [Ψ(P ′)−Ψ(P )] d−→
N(0,Σ), where the covariance matrix Σ can be estimated using the empirical covariance of
DPˆ
∗
(O). Confidence intervals for (2) can be derived via the delta method.
Having presented the high-level arguments for our TMLE, we devote the remainder of this
section to formally establishing the validity of this estimator. First, we derive the efficient
influence functions of the three parameters of interest. Next, we present a TMLE that
fluctuates an initial estimate of P so that (4) is satisfied. We then present a theorem giving
regularity conditions for the convergence in distribution to a multivariate normal, and we
also observe that these regularity conditions can be weakened via cross-validation. Finally,
we combine a log transformation with the delta method to demonstrate how to construct
confidence intervals for contrasts between the treatment-specific principally stratified risks.
3.2 Presentation of estimator
Per the above Motivation section, the efficient influence function of Ψ should play a major
role in estimation. Therefore, the following result, which presents an expression for the effi-
cient influence function, will be useful. Before presenting the result, we note that throughout
we will use the following conventions for any distribution P ′, function f , and realizations
(a, w) of (A,W ): EP ′ [f(O)|a, w] = EP ′ [f(O)|A = a,W = w] and P ′(a|w) = P ′(A = a|W =
w).
Theorem 2. Within the model M that at most places restrictions on the probability of
receiving treatment given baseline covariates, the parameter Ψ has efficient influence function
DP
′ ≡ (DP ′k : k = 1, 2, 3) at P ′, where, for k = 1, 2, 3,
DP
′
k (o) ≡
1{a = ak}
P ′(a|w) {fk(o)− EP ′ [fk(O)|ak, w]}+ EP ′ [fk(o)|ak, w]−Ψk(P
′).
Above, f1(o) ≡ 1S=s?1 and a1 = 1; f2(o) ≡ 1Y=1,S=s?1 and a2 = 1; and f3(o) ≡ 1Y=0,Sc=s?1 and
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a3 = 0.
The proof of this result is in Appendix A.2. It easy to verify that the remainder
Rem(P, P ′) ≡ (Remk(P, P ′) : k = 1, 2, 3) in (3) takes the following form:
Remk(P, P
′) = EP
[(
1− P (ak|W )
P ′(ak|W )
)
(EP ′ [fk(O)|ak,W ]− EP [fk(O)|ak,W ])
]
. (5)
Using this efficient influence function, it remains to develop an estimator satisfying (4). This
estimator is given in Algorithm 1, which independently estimates each parameter Ψk(P ),
k = 1, 2, 3, by invoking a TMLE for estimating EE[f(O)|A = a,W ] for an arbitrary function
f and treatment a. Many variants of this k-specific TMLE have been presented elsewhere
(e.g., van der Laan and Rose, 2011). We note here that we are in fact implementing three
separate TMLEs, and so it is not immediately obvious that there exists a single distribution
Pˆ ∗ such that our estimator is equal to Ψ(Pˆ ∗). We can show that a unique distribution exists
if Pˆ ∗2 (f2(O) = 1|a2, w) ≤ Pˆ ∗1 (f1(O) = 1|a1, w) for all w.
We now present the limiting distribution of the proposed estimator. This result relies on
the following conditions:
• Dˆ belongs to a fixed Donsker class (van der Vaart and Wellner, 1996) with probability
approaching one;
• ∫ [Dˆ(o)−D(o)]2dP (o) converges to zero in probability as n→∞;
• all remainders are negligible: maxk Remk(P, Pˆ ∗k ) = oP (n−1/2).
Theorem 3. Under the above listed conditions, there exists a covariance matrix Σ such that
n1/2
[
ψˆ −ψ
]
= n−1/2
n∑
i=1
DP (Oi) + oP (1)
d−→ Normal(0,Σ),
The proof of this result is omitted because very similar proofs have already appeared in the
literature many times (e.g., van der Laan and Rose, 2011; Kennedy, 2016, for overviews). The
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Algorithm 1 TMLE for Estimating Ψ1(P ), Ψ2(P ), and Ψ3(P )
Takes as input n observations Obs ≡ {Oi : i = 1, . . . , n}.
function TMLE(Obs)
Initial Estimates: Define an initial estimator Pˆ of P :
• The marginal distribution of W under Pˆ should be the empirical.
• Only the estimates of the components of P (O|W ) needed to evaluate Ψk and Dk,
k = 1, 2, 3, are needed: Pˆ (A = 1|W = ·), Pˆ (Y = 1|S = s?1, A = 1,W = ·),
Pˆ (S = s?1|A = 1,W = ·), and Pˆ (Y = 0, Sc = s?1|A = 0,W = ·).
. Conditional probability estimates should fall in (0, 1).
for k = 1, 2, 3 do . Recall the definitions of fk and ak from Theorem 2.
Fluctuation for Targeting Step: Using observations i = 1, . . . , n, fit the in-
tercept ˆk using an intercept-only logistic regression with outcome fk(Oi), offset
logit Pˆ {fk(O) = 1|a, w}, and weights 1Ai=akPˆ (Ai|Wi) .
Targeting Step: We now define a fluctuation of Pˆ ∗k of Pˆ , targeted towards esti-
mation of ψk. Define
Pˆ ∗k {fk(O) = 1|ak, w} ≡ expit
{
logit Pˆ {fk(O) = 1|ak, w}+ ˆk
}
.
The marginal distribution of W ∼ Pˆ does not need to be fluctuated.
Plug-In Estimator: The estimator of ψk is ψˆk ≡ Ψk(Pˆ ∗k ), and the estimate of the
corresponding component of the influence function is Dˆk ≡ DPˆ
∗
k
k .
return Estimate ψˆ ≡ (ψˆk : k = 1, 2, 3) and estimated influence function Dˆ ≡ (Dˆk :
k = 1, 2, 3).
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limiting covariance matrix Σ can be consistently estimated using the empirical covariance of
DPˆ
∗
k (O).
To develop sufficient conditions for maxk Remk(P, Pˆ
∗
k ) to be negligible, one can use that
each Remk(P, Pˆ
∗
k ) is upper bounded by a constant times the product of the root-mean-
square distance between Pˆ ∗k (ak|W = ·) and P (ak|W = ·) and the root-mean-square distance
between Pˆ ∗k (fk(O) = 1|ak,W = ·) and P (fk(O) = 1|ak,W = ·). In a parametric model,
each of these root-mean-square distances is OP (n
−1/2), and outside of a parametric model
sufficient smoothness will enable several estimators to ensure that the product of these two
rates is oP (n
−1/2). Examples include generalized additive models (Hastie and Tibshirani,
1990; Horowitz, 2009) and the highly adaptive lasso estimator (van der Laan, 2017). If the
data are generated from a randomized clinical trial, and the known treatment assignment
probabilities are used, then each Remk(P, Pˆ
∗
k ) is exactly zero.
The Donsker condition in the theorem above restricts the flexibility of the initial distri-
bution estimate Pˆ . This restriction may be unpleasant in situations where the dependence
of P {fk(O) = 1|a, w} on w is believed to be complicated. In these cases, one can modify
the above estimator via a V -fold sample splitting approach, resulting in a cross-validated
TMLE (Zheng and van der Laan, 2011). For ease of exposition, we focus on the case that
V = 10. Here, one partitions the data into ten mutually exclusive and exhaustive folds of
approximately equal size. One then fits ten initial estimates of Pˆ , where each initial estimate
leaves out a different one of these ten folds. For each observation i, let v(i) denote the fold
that contains i. Let Pˆ v denote the initial estimate based on the nine out of ten folds that
do not include fold v. The sample splitting procedure then replaces each evaluation of (a
conditional distribution of) Pˆ at Oi within the for loop over k by Pˆ
v(i), where we recall that
k indexes the three dimensions of the output of the parameter Ψ. A single, non-fold-specific
fluctuation ˆk is still returned from the logistic regression in this for loop. The fluctuated
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initial estimates are still fold-specific, with
Pˆ v,∗k {fk(O) = 1|a, w} ≡ expit
{
logit Pˆ v {fk(O) = 1|a, w}+ ˆk
}
.
The estimator of ψk is ψˆ
CV
k ≡ 1n
∑n
i=1 Ψk(Pˆ
v(i),∗
k ). The estimator ψˆ
CV
should have the same
multivariate normal limit as ψˆ would have if the Donsker condition is satisfied, but this cross-
validated TMLE will still have this multivariate normal limit even if this Donsker condition
fails.
As discussed in the introduction, the delta method can be used to derive confidence
intervals for any smooth mapping Γ : R3 → R of ψ, where the efficient influence function is
then 〈DP , Γ˙(ψ)〉, with Γ˙ the gradient of Γ. For a discrete biomarker, as is studied in this
section, this will require that the biomarker takes on the value s?1 with positive probability,
i.e. that E[P (S = s?1|A = 1,W )] > 0. For example, for the log of the relative risk defined
in (2), Γ(x) ≡ log(x2) − log(x1 − x3) and Γ˙(x) =
(−[x1 − x3]−1, x−12 , [x1 − x3]−1). For the
risk difference on treatment A = 1 versus on treatment A = 0, Γ(x) = (x2 − x3)/x1 and
Γ˙(x) = x−21 (x3 − x2, x1,−x1). In either case, the influence function of our estimator ψˆ can
be estimated using 〈Dˆ, Γ˙(ψˆ)〉. Letting σˆ2 denote the empirical variance of 〈Dˆ(O), Γ˙(ψˆ)〉, a
95% confidence interval for Γ(ψ) is given by Γ(ψˆ)± 1.96n−1/2σˆ.
4 Estimation Under Two-Phase Sampling
In some settings, such as in many vaccine studies, the post-treatment biomarker S and the
post-crossover biomarker Sc will only be measured on a subset of the subjects in the study.
For example, the biomarker S may be measured on all treated (A = 1) cases (Y = 1) and
all members of a prespecified cohort randomly drawn from the set of all subjects, whereas
the crossover biomarker Sc may be measured on a random subset of untreated (A = 0)
controls (Y = 0). In this section, we study estimation in the setting where the biomarkers
are discrete.
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Section 4.1 gives an overview of the notation and assumptions needed in this setting.
Section 4.2 presents an inverse probability weighted TMLE based on the framework of Rose
and van der Laan (2011). This estimator is appealing because it only requires minor modifi-
cations to the estimator from Section 3.2, namely in the inclusion of sampling weights. When
the baseline covariates are not discrete, the inverse probability weighted TMLE presented in
this section may not be efficient, because it does not fully leverage the predictive power of
the baseline covariates for the missing biomarker, which is especially important for subjects
for whom these biomarkers are not measured. Though Rose and van der Laan (2011) also
presented a TMLE that can attain efficiency in settings where the baseline covariates are
continuous, we instead present a one-step estimator for these settings, that has the advan-
tage of being easier to describe and implement, but the disadvantage of not being a plug-in
estimator.
4.1 Overview
For treated subjects, let ∆ denote the indicator of having the biomarker S measured. For
untreated subjects, let ∆ denote the indicator of having the crossover biomarker Sc measured.
We use the convention that ∆ is always one for untreated cases, which does not cause a
problem because Sc is defined to be zero for all untreated cases.
We make the missing at random assumptions that the indicator ∆ is independent of
the biomarkers (S, Sc) given phase-one information (W,A, Y ), where we recall that S is
degenerate for untreated subjects and Sc is degenerate for treated subjects and untreated
controls. For each subject i, the indicator of having the biomarker measured is given by
∆i. We suppose that ∆1, . . . ,∆n is an i.i.d. sequence given (O1, . . . , On), where we remind
the reader that Oi ≡ (Wi, Ai, Si, Yi, Sci ). We let O˜ ≡ (W,A,∆S, Y,∆Sc) denote the censored
data structure, which is equal to O except that the biomarkers are unobserved for all subjects
with ∆ = 0. Let P˜ denote the corresponding distribution of (∆, O˜). Our estimation scheme
will be a function of the observed n i.i.d. draws of O˜ ∼ P˜ .
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Let Π(O˜) denote the probability that ∆ = 1 given O˜. For brevity, we let pi ≡ Π(O˜) for
an arbitrary O˜ ∼ P˜ and, for each subject i, we let pii ≡ Π(Oi). We note that pii = 1 for all
untreated cases. Furthermore, in a case-cohort sampling scheme, pii = 1 for all treated cases.
4.2 Inverse Probability Weighted TMLE
In this section, we will assume that pii is known for each subject. If pii only relies on W
through a discrete coarsening V of W , then the inference that we propose will be valid,
albeit conservative, if pii is replaced by a nonparametric maximum likelihood estimator pˆii
of the probability that ∆ = 1 conditional on (V,A, Y ). In fact, using this nonparametric
maximum likelihood estimator typically leads to asymptotic efficiency gains even in our
setting where pii is known, and never leads to a loss of asymptotic efficiency in this setting
(Theorem 2.3 of van der Laan and Robins, 2003).
Defining the inverse probability weighted (IPW) TMLE requires only minor modifications
to Algorithm 1. The modifications to our estimation scheme hinge on the fact that, for any f ,
EP [f(O)] = EP˜ [∆pi−1f(O˜)]. This fact is useful both when f is a loss function, in which case
it suggests to include weights ∆pi−1 in the estimation procedure, and when f is an influence
function, in which case it suggests to weight DP in the leading term on the right-hand side
of (3). The estimation scheme, which represents a two-phase sampling TMLE as presented
in Rose and van der Laan (2011), is presented in Algorithm 3 in Section 4. When obtaining
the initial estimate Pˆ of P , one can use loss-based approaches, e.g. minimizing the empirical
mean-squared error or Kullback-Leibler divergence to estimate the needed components of
P . The key in the two-phase sampling case is to include the inverse of the (estimated)
subject-level probabilities for belonging to the second phase as weights, i.e. including as
weights ∆ipi
−1
i , in whatever loss-based estimation procedure that is used to estimate the
needed components of P (see Section 3.2.2 of Rose and van der Laan, 2011).
Confidence intervals for the IPW TMLE can again be constructed using that, under reg-
ularity conditions closely related to those of Theorem 3, n1/2[ψˆ−ψ] d−→ Normal(0, Σ˜). The
17
covariance matrix Σ˜ can be estimated by the empirical covariance of the inverse weighted in-
fluence function
(
∆ip¯i
−1
i Dˆk(O˜i) : k = 1, 2, 3
)
, where p¯ii is defined in Algorithm 3 as a rescaling
of pii that ensures that ∆p¯i
−1 has empirical mean one within both the treated and untreated
strata of the observations. The only difference relative to the estimation of Σ is that the
influence function is now weighted by ∆ip¯i
−1
i . Confidence intervals for the relative risk can
again be generated using the delta method.
4.3 One-Step Estimator that Fully Leverages Continuous Baseline
Covariates
We now present a one-step estimator that fully leverages the predictive power of baseline
covariates, treatment status, and endpoint status for the missing values of the biomarker.
Under some regularity conditions, this estimator is efficient in the model in which the prob-
ability of treatment given covariates is unknown, and is only slightly inefficient in settings
where the probability of treatment given covariates is known (Marsh, 2016). In the setting
where the treatment mechanism is unknown, the efficient influence function is given by
D˜P
′
(o˜) ≡ δpi−1DP ′(o˜) + (1− δpi−1)EP ′ [DP ′(O˜)∣∣∣∆ = 1, a, w, y] ,
where o˜ ≡ (w, a, δs, y, δsc) and we abuse notation and let pi = Π(o˜). The elements of the
above vector rewrite as
D˜P
′
k (o˜) ≡
1{a = ak}
P ′(a|w)
{
δpi−1fk(o) +
(
1− δpi−1)EP ′ [fk(O)|∆ = 1, a, w, y]− EP ′ [fk(O)|ak, w]}
+ EP ′ [fk(o)|ak, w]−Ψk(P ′), (6)
To define our estimator, we first suppose that we have an estimator Pˆ of the distribution P
of the data that would have been observed had the probability of membership in the second
phase of sampling been equal to one for all subjects. This estimator can be obtained via
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loss-based learning using inverse probability weighting (see Section 3.2 of Rose and van der
Laan, 2011). Next, we define our estimator as ψˆ ≡ Ψ(Pˆ ) + 1
n
∑n
i=1 D˜
P ′(O˜i). Let Σˆn denote
the empirical covariance matrix of D˜P
′
(O˜i), i = 1, . . . , n, where here we acknowledge the
notational overload with the covariance matrix Σˆn from Section 3.2 (single-phase sampling).
Under some conditions, one can show that n1/2Σˆ
−1/2
n
[
ψˆ −Ψ(P )
]
d−→ N(0, Id), where Id
denotes the 3× 3 identity matrix. One can then use the delta method to develop confidence
intervals for any contrast based on the principally stratified means ψ, such as the log relative
risk.
To gain some intuition on this estimator, note that, if the baseline covariates are strongly
predictive of the biomarker among treated subjects and of the crossover biomarker among
uninfected untreated subjects, then the estimate of EP [fk(O)|∆ = 1, a, w, y] will be approx-
imately equal to fk(o). Therefore, δpi
−1fk(o) + (1− δpi−1)EP ′ [fk(O)|∆ = 1, a, w, y] is ap-
proximately equal to fk(o), so that D˜
P ′
k (o˜) is approximately equal to the efficient influence
function in the setting where phase two information is observed on everyone.
Finally, we note that, though we have assumed that Π is known, the proposed one-step
estimator will also yield valid inference if Π is replaced by an estimate and a doubly robust
term is negligible.
5 Continuous Biomarker
5.1 Algorithm and Theoretical Guarantees
Thus far we have assumed that the biomarker is discrete. Suppose now that the biomarkers
S1, S
c
0 are continuous, with support in R. We will show the methods that we have proposed
immediately extend to this case once one replaces the indicators that S = s?1 and S
c = s?1
by kernels. The extension to the case that the biomarkers have support in Rd, d > 1, is
straightforward by using kernels for Rd-valued data, though, given that kernel smoothers are
highly susceptible to the curse of dimensionality, we expect that this method will only yield
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informative estimates when d is small. For simplicity, we consider the full sampling case
where all treated subjects and all untreated subjects without the event have their biomarker
measured. As in the previous section, our objective will be to estimate the effect of treatment
conditional on a biomarker value s?1.
This treatment effect will be a function of three parameters, which are defined with
respect to the (conditional) Lebesgue densities of the biomarkers S and Sc, which are assumed
to exist. To avoid introducing new notation for these densities, we will abuse notation so that
writing “S = s” or “Sc = s” in a conditional probability statement refers to the conditional
density of S or Sc at s. Once we have made this abuse of notation, the definition of Ψ(P )
from Section 2 does not need to be changed to study the setting where the biomarkers are
continuous. So, for example, Ψ1(P
′) ≡ EP ′ [P ′(S = s?1|A = 1,W )] represents the Lebesgue
density of S at s?1, conditional on A = 1 and W , averaged across values of W ∼ P ′.
Let K denote a kernel in R, where this function is centered at zero and integrates to one.
Examples of kernels include K(x) = 1{−1 ≤ 2x ≤ 1} (uniform kernel), K(x) ∝ exp(−x2/2)
(Gaussian kernel), and K(x) ∝ 1
2
(3− x2) exp(−x2/2) (fourth-order Gaussian kernel), where
the constants in the ‘∝’ statements are chosen so that the kernels integrate to one. The
first two kernels are second-order in the sense that
∫
xtK(x)dx = 0 for t = 1, whereas the
final kernel is fourth-order in the sense that
∫
xtK(x)dx for t = 1, 2, 3. Generally, a kernel
is of order r if
∫
xtK(x)dx = 0 for all t = 1, . . . , r − 1. We define Kh as the function
x 7→ h−1K[xh−1], where h > 0 is the bandwidth.
Before presenting our algorithm, we introduce the kernel-dependent pseudo-outcomes
that we will use to replace fk, k = 1, 2, 3. In particular, we define f1,h(Oi) ≡ Kh(S − s?1),
f2,h(Oi) ≡ 1Y=1 Kh(S − s?1), and f3,h(Oi) ≡ 1Y=0 Kh(Sc − s?1). We continue to use the
definitions a1 = 1, a2 = 1, and a3 = 0. For an arbitrary P
′, we also define DP
′
k,h analogously to
DP
′
k from Theorem 2, but with each instance of fk replaced by fk,h. We also define a smoothed
version of our parameter. To do this, it will be useful to make the dependence of Ψ(P ) on
s?1 explicit in the notation: in particular, we define Ψ(P ; s) ≡ {Ψk(P ; s) : k = 1, 2, 3} for all
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s in the support of S|A = 1 under P . We now define and give an equivalent expression for
the kernel-smoothed version of Ψ(P ; s?1):
Ψh(P ) ≡
∫
Ψ(P ; s)Kh(s− s?1)ds = E [E [fk,h(O)|ak,W ]] . (7)
The equivalent expression relies on changing the order of integration between the integral
over s and the integral over W ∼ P . We write the three components of Ψh(P ) as Ψk,h(P )
for k = 1, 2, 3. It will be convenient to define qk,h as the function w 7→ E [fk,h(O)|ak, w].
Our proposed estimation procedure is presented in Algorithm 2. In our procedure, we
estimate qk,h for each k = 1, 2, 3, and so by the latter identity in (7) it follows that we can
use these expectations to evaluate Ψh at our estimated distribution.
Our estimator can be analyzed using standard arguments for kernel estimators. We will
break our analysis into a study of the bias and a study of the variance of our estimator.
We will show that our estimator has small bias for the smoothed principally stratified mean
vector Ψh(P ) at a user-defined value of h. Therefore, the bias of our estimator for Ψ(P ) will
be driven by the convergence of a kernel-smoothed parameter to the true target parameter.
As is standard for kernel estimators, the rate of convergence of the bias will be driven by
the differentiability of s 7→ Ψ(P ; s) at s and by the order of the kernel that we select.
Theorem 4 (Bias for Unsmoothed Parameter). Let K be an rth-order kernel and sup-
pose that, for each k ∈ {1, 2, 3}, s 7→ Ψk,h(P ; s) is (t + 1)th-order differentiable on the
real line with uniformly bounded (t + 1)th derivative. If
∫ |umin{r,t+1}K(u)|du < ∞, then
‖Ψh(P )−Ψ(P )‖ = O(hmin{r,t+1}).
Next, we study the variance of our estimator, which is (asymptotically) unbiased for the
parameter evaluated at the kernel-smoothed data generating distribution. Before presenting
this result, we will define the covariance matrix Σn to be used in the upcoming theorem. For
q¯k equal to the limit of the estimates of qk,hˆn as n → ∞ (see the upcoming Condition A4)
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Algorithm 2 CV-TMLE for Estimating Ψ1(P ), Ψ2(P ), and Ψ3(P ) when the biomarker is
continuous
Takes as input n observations Obs ≡ {Oi : i = 1, . . . , n} and a kernel Kh.
For simplicity, focus on 10-fold cross-validation.
function CV-TMLE(Obs)
for v = 1, . . . , 10 do
Initial Estimates: Using data from training set v, define an initial estimator Pˆ v
of P :
• The marginal distribution of W under Pˆ v should be the empirical of the ob-
servations in training set v.
• Using only observations in the training set v, compute an estimate w 7→
Pˆ v(A = 1|w) of w 7→ P v(A = 1|w), and an estimate w 7→ qˆvk,h(w) of
w 7→ qk,h(w).
. Each qk,h should have range in (0,∞).
for k = 1, 2, 3 do
Fluctuation for Targeting Step: Define ˆk as a minimizer (in real-valued ) of(
1
n
n∑
i=1
1Ai=ak
Pˆ v(Ai|Wi)
[
fk,h(Oi)− exp
{
log qˆ
v(i)
k,h (Wi) + 
}])2
.
Targeting Step: For each fold v, define
qˆv,∗k,h(w) ≡ exp
{
log qˆvk,h(w) + ˆk
}
.
The marginal distribution of W ∼ Pˆ does not need to be fluctuated.
Estimator: The estimator of ψk,h is
1
n
∑n
i=1 Ψk,h(Pˆ
v(i),∗
k,h ), and, for each subject i,
the estimate of the corresponding component of the smoothed influence function is
Dˆk,h,i ≡ DPˆ
v(i),∗
k,h
k,h .
return Estimate ψˆh ≡ (ψˆk,h : k = 1, 2, 3) and estimated smoothed influence function
Dˆh,i ≡ (Dˆk,h,i : k = 1, 2, 3).
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and  ∈ R, we let
gk,,h¯n(o) ≡
1a=ak
P (ak|w)
[
fk,h¯n(o)− exp {log q¯k(w) + }
]
+ exp [log q¯k(w) + ] (8)
and define Σn as the 3 × 3 matrix representing the covariance matrix under O ∼ P of(
h¯
1/2
n gk,¯k,h¯n(O) : k = 1, 2, 3
)
, where ¯k, k = 1, 2, 3, is defined in the upcoming Condition A9.
The following theorem relies on conditions that are stated in the upcoming Section 5.2.
Theorem 5 (Estimation of Smoothed Parameter). If Conditions A4 through A10 hold, then
(nhˆn)
1/2Σ−1/2n
[
ψˆhˆn −Ψhˆn(P )
]
d−→ N(0, Id). (9)
The proof of this result is given in Appendix B. Under mild conditions, the Σn ma-
trices will be consistently estimable via the cross-validated empirical covariance matrix
Σˆn ≡ 1n
∑n
i=1 Dˆhˆn,i[Dˆhˆn,i]
T .
Note that Ψhˆn(P ) is a data adaptive parameter (van der Laan et al., 2013), in the
sense that it is random through the bandwidth hˆn. One of the conditions for the theorem,
listed in the next subsection, is that there exists a deterministic sequence h¯n such that
hˆn/h¯n → 1 + oP (h¯1/2n ). In fact, many selection procedures satisfy the (typically stronger)
condition that hˆn/h¯n − 1 = OP (n−1/2) for a deterministic sequence h¯n (Chiu, 1991; Hall
et al., 1991; Fan and Marron, 1992). Under these stronger conditions, the difference between
the data adaptive smoothed parameter at bandwidth hˆn and the sample size dependent, but
deterministic, smoothed parameter at bandwidth h¯n is of the order n
−1/2, so that one can
replace the data adaptive parameter by Ψh¯n(P ) in the above theorem without changing the
result.
An estimator of the smoothed relative risk RRPh (s
?
1) ≡ Ψ2,h(P )/[Ψ3,h(P ) − Ψ1,h(P )] is
given by R̂Rhˆn(s
?
1) ≡ ψˆ2,hˆn/[ψˆ3,hˆn− ψˆ1,hˆn ]. Similar delta method arguments used to develop
confidence intervals for discrete biomarkers can be used in the continuous setting. Then,
Wald-type confidence intervals for the log smoothed relative risk can be defined by using
23
that, under the conditions of Theorem 5, (nhˆn)
1/2σˆ−1
hˆn
[log R̂Rhˆn(s
?
1)− log RRPhˆn(s?1)] converges
to a standard normal distribution, where, for Γ˙(x) =
(−x−12 ,−[x1 − x3]−1, [x1 − x3]−1), we
define
σˆ2
hˆn
≡ 1
n
n∑
i=1
[
〈Dˆhˆn,i, Γ˙(ψˆhˆn)〉 −
1
n
n∑
j=1
〈Dˆhˆn,j, Γ˙(ψˆhˆn)〉
]2
.
Combining the above two theorems demonstrates that there are rates for h¯n such that
asymptotically normal inference is possible for the unsmoothed parameter RRP (s?1). Indeed,
balancing the standard error of ψˆhˆn , i.e. O((nhˆn)
−1/2), and its bias for estimating the
unsmoothed parameter, i.e. O(hmin{r,t+1}) for r, t defined in Theorem 4, shows that the bias
converges more quickly than the standard error if h = o(n−1/(2 min{r,t+1}+1)). Nonetheless,
selecting these rates for h¯n requires undersmoothing, i.e. choosing a rate for h¯n that is
slower than the rate that is optimal according to a criterion such as the mean-squared error
of a density estimator at S = s1, conditional on A = 1. Following the estimation of the
causal effect of continuous treatments in Kennedy et al. (2016), who himself followed the
suggestion of Wasserman (2006), we focus our inference solely on the smoothed relative risk
parameter, rather than on the original, unsmoothed parameter. The rate of decay on the
bias from the above theorem is still interesting: it shows that this smoothed parameter is
getting close to the unsmoothed parameter as the sample size grows. Nonetheless, we do not
attempt to quantify the proximity of the smoothed parameter to the unsmoothed parameter
in the confidence interval that we construct. Once one has adopted this perspective, one
has flexibility in selecting the bandwidth h. For example, one could use a cross-validated
mean integrated squared error criterion, where this criterion is selected for estimating the
marginal density of S among all treated subjects.
An alternative approach would be to use the recent work of (Bibaut and van der Laan,
2017), that enables principled selection of an undersmoothed bandwidth for non-pathwise-
differentiable parameters such as Ψ. Consideration of the performance of this method for
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the estimation of Ψ is beyond the scope of this work.
5.2 Conditions for Asymptotically Normal Estimation of the Smoothed
Parameter
Theorem 5 used the following conditions to prove the asymptotic normality of the estimator
for continuous biomarkers:
(A4) The treatment mechanism estimates satisfy maxv
∥∥∥Pˆ v(a|W = ·)− P (a|W = ·)∥∥∥ = oP (1).
Furthermore, for k = 1, 2, 3, there exists a function q¯k such that maxv
∥∥∥qˆv
k,hˆn
− q¯k
∥∥∥ =
oP (1).
(A5) There exists a deterministic positive sequence {h¯n}∞n=1 such that hˆn/h¯n → 1+oP (h¯1/2n )
and nh¯n diverges to infinity.
(A6) maxv
∥∥qˆvk,h − qk,h∥∥∥∥∥Pˆ v(ak|W = ·)− P (ak|W = ·)∥∥∥ = oP (n−1/2hˆ−1/2n ).
(A7) The kernel K can be evaluated using a composition of a finite number of arithmetic
operations (+, −, ÷, ×), indicator functions (x 7→ 1{x > c} for a constant c), and
exponential functions (x 7→ ex). Furthermore, the kernel K is bounded and uniformly
continuous.
(A8) There exists a constant c > 0 such that P{c−1 < mink,v qˆvk,h(W ) ≤ maxk,v qˆvk,h(W ) <
c} = 1− oP (1) and a constant δ > 0 such that P{maxk,v,a 1/Pˆ vk (a|W ) < δ−1} = oP (1).
(A9) For each k ∈ {1, 2, 3}, there exists a fixed ¯k ∈ R such that ˆk,n → ¯k in probability as
n→∞, where here (and here only) we make the dependence of ˆk on n explicit in the
notation by denoting this quantity by ˆk,n.
(A10) There exists some fixed δ > 0 such that, with probability approaching one, all of the
eigenvalues of Σn are bounded below by δ.
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We now discuss these conditions.
Condition A4. This condition requires mean-square consistency of the needed nuisance
parameter estimates, where we require this consistency for the estimators within each training
fold. If the same estimators are used within each training fold, then this is equivalent to
requiring mean-square consistency of the estimation of the needed nuisance parameters on
the full sample. This condition does not require any rate for this convergence, and so is a
minor assumption relative to A6, though we note that A4 is not necessarily implied by A6
(e.g., if the treatment mechanism is known and one uses this information in estimation). Note
that here we have assumed that the treatment mechanism estimates converge to the true
treatment mechanism in mean-square, whereas we have only required that qˆv
k,hˆn
has some
limit. The condition on the treatment mechanism seems minor given that the treatment
mechanism is known in most settings where crossover designs would be employed.
Condition A5. This condition requires that the bandwidth selection procedure that is
employed will eventually return a (nearly) deterministic result. The procedures of (Chiu,
1991; Hall et al., 1991) yield data-driven bandwidth selections hˆn that satisfy hˆn/h

n =
1 +OP (n
−1/2), where here hn is the optimal bandwidth in terms of mean integrated squared
error. In fact, Fan and Marron (1992) demonstrates that the OP (n
−1/2) term quantifying the
multiplicative deviation of these bandwidth selection procedures from the optimal bandwidth
is optimal even in terms of the leading constant. Therefore, if one selects hˆn to optimize an
estimate of the density of S among treated subjects, we expect that the selected bandwidth
will eventually behave as a deterministic sequence and therefore that A5 will be satisfied.
Condition A6. This condition requires that product of the estimates of the treatment
mechanism and the smoothed densities qk,h converge to zero faster than does the standard
error of our estimator. If the treatment mechanism is known, as is the case in a randomized
trial, then one can ensure that this product is exactly zero at every sample size. Otherwise,
the plausibility of this condition will typically rely on the dimensionality of W . As a reference
point, we note that, if a parametric model could be correctly specified for an unknown
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treatment mechanism, then this condition would also automatically be satisfied if hˆn → 0 in
probability, since in this case the product from this condition would be OP (n
−1/2).
Condition A7. This condition does not rely on the data or the data generating distribution
and therefore can be verified in applications. We use this condition to ensure certain empirical
process and envelope conditions that we use in our proof are satisfied. This condition is
satisfied by most kernels used in practice. For example, it is satisfied by K(x) = 1{−1/2 ≤
x ≤ 1/2} (uniform kernel), K(x) = exp(−x2/2) (Gaussian kernel), and K(x) = 1
2
(3 −
x2) exp(−x2/2) (fourth-order Gaussian kernel).
Condition A8. This assumption ensures that our estimates both of the density qk,h and
of the treatment mechanism do not fall too close to zero or one, and can be enforced in
practice via truncation. For the truncation not to damage the chance of the consistency
of these estimates in A6, Condition A8 requires that the true treatment mechanism does
not fall too close to zero or one. This will be plausible for the treatment mechanism in
a randomized trial in which all subjects have a non-negligible probability of receiving or
not receiving treatment. The assumption on the density qk,h requires that, within each
stratum of covariates, any given realization of the biomarker is not very rare or very likely.
Furthermore, the assumption on qk,h requires that the probability of having Y = 1 within
baseline covariate strata of subjects not receiving treatment at baseline is never too common
(this is to be expected for rare events), and also that the event probability is bounded away
from zero among treated subjects within each stratum of baseline covariates.
Condition A9. The existence of a limit ¯k for ˆk can be ensured under mild conditions using
arguments for Z-estimators (van der Vaart and Wellner, 1996). We omit these arguments
here for brevity.
Condition A10. This condition aims to ensure that the limit is non-degenerate. Its plausi-
bility can be checked in practice by checking the size of the eigenvalues of the estimator Σˆn
of Σn, given by Σˆn ≡ 1n
∑n
i=1 Dˆhˆn(Oi)[Dˆhˆn(Oi)]
T , and ensuring that the smallest eigenvalue
is not close to zero.
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6 Simulation
We conduct simulations similar to the settings in Gilbert and Hudgens (2008), though with
continuous rather than discrete baseline covariates and biomarker. Here we focus on a
univariate post-treatment biomarker because such biomarkers are often of interest in vaccine
studies (see Corey et al., 2015, for examples). We consider sample size 5000 with equal
number of people in treatment A = 1 and control A = 0. We generate (W,S1) from bivariate
normal distribution with mean (0.41, 0.41)T and covariance matrix
 0.552 0.552 · 0.5
0.552 · 0.5 0.552
 .
For a = 0, 1, we generate the potential outcome from the logistic model
P F (Ya = 1|W,S1) = expit(β0 + β1a+ β2W + β3S1 + β4aS1)
where expit(x) ≡ exp(x)/(1 + exp(x)) and β0 = 1.2, β1 = −0.6, β2 = −0.5, β3 = −0.1, β4 =
−0.9, such that the average disease rate is 9.5% among subjects receiving A = 1 and is
18.8% among subjects receiving A = 0. We consider a full sampling setting where all treated
subjects (A = 1) and all untreated controls (A = 0, Y = 0) have the biomarker measured. We
consider Gaussian kernel Kh(x) =
1√
2pih
exp(− x2
2h2
) to smooth 1{S1 = s∗1}. We use R package
SuperLearner (Polley and van der Laan, 2012) to estimate the kernel-smoothed Ψh(P ) in
equation (7). We consider GLM, GLM with interaction, stepwise regression, neural network
and sample mean in our SuperLearner library, whose corresponding wrapper functions in the
SuperLearner package are respectively given by SL.glm, SL.glm.interaction, SL.step,
SL.nnet, SL.mean. All of these functions were run at their default settings in version 2.0-22
of the SuperLearner package.
We calculate two versions of the true parameters: one without smoothing and one with
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smoothing. The true parameter without smoothing can be derived from the following identity
Ψ1(P ; s
∗
1) = P
F (S1 = s
∗
1)
Ψ2(P ; s
∗
1) =
∫
P F (Y1 = 1|S1 = s∗1,W = w)P F (S1 = s∗1,W = w)dw
Ψ3(P ; s
∗
1) =
∫
P F (Y0 = 0|S1 = s∗1,W = w)P F (S1 = s∗1,W = w)dw
The target parameter is log relative risk Ψh = log(
Ψ2,h
Ψ1,h−Ψ3,h ). The smoothed version of the
true parameter is calculated by (7). We calculate the 95% Wald-type confidence interval
and its coverage over the unsmoothed true parameter and smoothed true parameter across
1000 simulations with different kernel bandwidth h. Figure 1 shows the confidence interval
coverage for a fixed s∗1 = 0.6 with different choices of h. The coverage probability for the
unsmoothed vaccine efficacy parameter drops below the nominal level when h is small or
large. The coverage probability for the smoothed parameter drops below the nominal level
when h is small but does not drop below nominal level when h is large. The results are
similar for other values of s∗1.
The primary results that we present in the main text will be based on a bandwidth
of 0.2. We selected this bandwidth by first noting the three places that the bandwidth is
used in our procedure: first, to estimate the density of S|A = 1,W that appears in the
definition of Ψ1; next, to estimate the density of S|A = 1, Y = 1,W that appears in the
definition of Ψ2; and, finally, to estimate the density of S
c|A = 0, Y = 0,W that appears in
the definition of Ψ3. To simplify selection of the bandwidth, we considered the estimation
of the corresponding densities when the covariate W was not conditioned on, namely the
estimation of the densities of (S|A = 1), (S|A = 1, Y = 1), and (Sc|A = 0, Y = 0).
Since Y is a rare outcome, the sparsest stratum in these conditioning statements will occur
in the second listed density, namely the density of S|A = 1, Y = 1. Consequently, we
expect that the bandwidth selection should be driven by the estimation of Ψ2. To select
the bandwidth for our simulations, we generated many data sets of size 5000, estimated the
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Figure 1: The coverage probability for the unsmoothed vaccine efficacy parameter drops
below the nominal level when h is small or large. The coverage probability for the smoothed
vaccine efficacy parameter drops below the nominal level when h is small but does not drop
below nominal level when h is large.
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density of S|A = 1, Y = 1, and evaluated the default bandwidth selected by the density
function in R; this default bandwidth is selected based on Eq. 3.31 of Silverman (1986).
We found that values of approximately 0.15 were typically selected. Because the densities
used in the definitions of Ψ1, Ψ2, and Ψ3 are defined conditionally on W , we inflated this
selected bandwidth to 0.2 to define the primary bandwidth considered in the main text. In
Appendix E we also present results at bandwidths of 0.1, 0.3, and 0.4.
Table 1 shows the bias, standard error, and coverage probability of the unsmoothed
and smoothed truth for different s∗1 with bandwidth chosen to be 0.2. The proposed TMLE
estimator has low bias and is asymptotically unbiased. As expected, the coverage probability
for the smoothed vaccine efficacy parameter is better than the coverage probability for the
unsmoothed vaccine efficacy parameter. Our additional simulation results for bandwidths
0.1, 0.3, and 0.4 are given in Appendix E. These results continue to show appropriate coverage
of the smoothed parameter, though, as expected, when the bandwidth is large we see poorer
coverage of the unsmoothed parameter.
s∗1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
Bias, Truth -0.02 -0.01 -0.00 0.01 0.02 0.03 0.04 0.05 0.07 0.09
Bias, Smoothed -0.01 -0.02 -0.02 -0.01 -0.01 -0.01 -0.01 -0.00 0.01 0.03
Standard Error 0.18 0.17 0.17 0.17 0.17 0.18 0.19 0.21 0.23 0.27
Coverage, Truth 0.95 0.95 0.95 0.95 0.94 0.95 0.95 0.96 0.96 0.97
Coverage, Smoothed 0.96 0.95 0.95 0.94 0.93 0.94 0.95 0.95 0.96 0.96
Table 1: Bias, standard error, and coverage probability of the log relative risk point estimator
and confidence intervals for different s∗1 values with bandwidth chosen to be 0.2.
7 Discussion
We have presented a targeted minimum loss-based estimator (TMLE) for estimating con-
trasts between the principally stratified means of absorbent endpoints in a crossover de-
sign, where we recall that an absorbent endpoint is an endpoints whose occurrence ren-
ders any subsequent measures of the biomarker of interest scientifically uninteresting. For
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most biomarkers, death is an absorbent endpoint. In HIV vaccine trials, HIV infection is
an absorbent endpoint when the biomarker of interest is the immune response. We have
established sufficient conditions for the nonparametric identifiability of treatment-specific
principally stratified means. Our identifiability conditions do not require that the baseline
covariates be discrete. We also established a necessary and sufficient condition for the falsi-
fiability of our assumption that relates the conditional distribution of the biomarker in the
population that was treated at baseline to the conditional distribution of the biomarker in
the population that was treated at the crossover stage. An implication of this result is that
the crossover assumption can be tested: if the test fails to reject, then there is no evidence in
the data that the crossover assumption is falsifiable. If the test rejects, then there is evidence
in the data that the crossover assumption is false.
Our proposed method does not handle right-censoring on the absorbent endpoint. When
dropout is rare, this will at most induce a small amount of bias in an estimate of the
principally stratified mean outcomes. When dropout is more common but rare enough that
a reasonable proportion of subjects have follow-up to the end of the study, the methods in this
work can be readily extended by incorporating inverse probability of censoring weights to the
proposed estimators. When few subjects have follow-up until the end of the study, further
methodological development is needed to develop low-variance estimators that account for
dropout.
When the biomarker is continuous, our proposed method relies on a choice of bandwidth.
Though our theoretical results provide guarantees for a wide range of sequences of selected
bandwidths, we have given only limited discussion to how the bandwidth should be selected
in practice. We did present one heuristic strategy in our Section 6, which involves using
existing bandwidth selection approaches for estimating the conditional density of S given
that A = 1 and Y = 1 – this density is related to a density that appears in the definition of
the parameter Ψ2. We leave the theoretical analysis of this and other bandwidth selection
strategies to future work.
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Our proposed estimators are especially advantageous in settings where (i) the baseline
covariates are predictive of the post-treatment biomarker and (ii) the relationship between
these baseline covariates and the biomarker is complex. The predictiveness of the baseline
covariates improves the plausibility of the identifiability assumption linking the biomarker
measured in treated individuals to the biomarker measured in untreated individuals following
their crossover to treatment. In these settings, obtaining statistical inference for the contrast
of interest using existing methods relies on either ignoring the baseline covariates, discretizing
the baseline covariates, or assuming a parametric relationship between the biomarker and
these baseline covariates. Our proposed TMLE is especially compelling in these settings
because it enables the incorporation of flexible estimation techniques for the conditional
distribution of the biomarker given the baseline covariates, while still admitting statistical
inference.
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Appendix
A Proofs of Results from Main Text
A.1 Identifiability
A.1.1 Identifiability under A1, A2, and A3
Proof of Theorem 1. Proof of 1. Using that P F (S1 = s
?
1) = E
F [P F (S1 = s
?
1|W )], ignorability
shows that P F (S1 = s
?
1|A = 1,W ), and consistency then shows that the right-hand side is
equal to E[P (S = s?1|A = 1,W )].
Proof of 2. Using that P F (Y1 = 1, S1 = s
?
1) = E
F
[
P F (Y1 = 1, S1 = s
?
1|W )
]
, ignorability
shows that P F (Y1 = 1, S1 = s
?
1|W ) = P F (Y1 = 1, S1 = s?1|A = 1,W ), and consistency shows
that the right-hand side is equal to E [P (Y = 1, S = s?1|A = 1,W )].
Proof of 3. Note that
P F (Y0 = 0, S1 = s
?
1) = E
F
[
EF
[
1{Y0=0,S1=s?1} |W
]]
(Tower Property)
= EF
[
P F (S1 = s
?
1|Y0 = 0,W )P F (Y0 = 0|W )
]
(Simplification)
= EF
[
P F (Sc0 = s
?
1|Y0 = 0,W )P F (Y0 = 0|W )
]
(A3)
= EF
[
P F (Y0 = 0, S
c
0 = s
?
1|W )
]
(Simplification)
= EF
[
P F (Y0 = 0, S
c
0 = s
?
1|A = 0,W )
]
(A2)
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= E [P (Y = 0, Sc = s?1|A = 0,W )] . (A1)
A.1.2 Non-Falsifiability of A3
We now show that A3 is not falsifiable from the observed data if Ψ4(P ) = 0. We do this by
constructing a distribution that is consistent with the observed data (in the sense of A1),
satisfies the ignorability assumption A2, and satisfies the crossover assumption A3. This
shows that, if Ψ4(P ) = 0, then we cannot falsify A3 from the observed data, even as the
sample size approaches infinity.
Theorem A.1. If Ψ4(P ) = 0, then condition A3 is not falsifiable from the observed data.
Proof. Suppose that Ψ4(P ) = 0. We establish that A3 is not falsifiable by showing that there
exists a distribution P F1 such that, if P
F = P F1 , then A1, A2, and A3 hold. Consider the
distribution P F1 , defined by its conditional densities (with respect to appropriate dominating
measures):
pF1 (y1|sc0, y0, s1, a, w) = p(y|A = 1, s1, w),
pF1 (s
c
0, |s1, y0, a, w) = p(Sc = sc0|Y = 0, A = 0, w)
pF1 (s1, y0|a, w) =

p(Sc = s1, Y = 0|A = 0, w), if y0 = 0
p(S = s1|A = 1, w)− p(Sc = s1, Y = 0|A = 0, w), if y0 = 1,
pF1 (a, w) = p(a, w).
Given that P is a probability measure, clearly, the first, second, and fourth conditional
densities are everywhere nonnegative and sum to one. The third conditional density is
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nonnegative because Ψ4(P ) = 0 and sums to one since
∑
s1
∑
y0
pF1 (s1, y0|a, w) =
∑
s1
p(S = s1|A = 1, w) = 1.
Condition A2 is easily established for the above since a does not appear on the right-hand side
of any of the density definitions except for the definition of pF1 (a, w). To establish A1, the only
challenge is in showing that pF1 (s1|w) = p(S = s1|A = 1, w) and pF1 (y0|w) = p(Y = y0|A =
0, w), but these results both follow by respectively summing pF1 (s1, y0|a, w) over y0 and s1.
Furthermore, note that A3 holds if P F = P F1 , since, for all s1, the fact that S1 is independent
of A, Sc0 given W shows that p
F
1 (S1 = s1|Y0 = 0, w) equals p(Sc = s1|Y = 0, A = 0,W ), and
A1 and A2 show that p(Sc = s1|Y = 0, A = 0,W ) = pF1 (Sc0 = s1|Y0 = 0, w).
A.2 Estimation when Biomarker is Discrete
Proof of Theorem 2. It is well known (van der Laan and Robins, 2003) that, for an arbi-
trary bounded function f : O → R, a ∈ {0, 1}, and parameter Φf,a defined by Φf,a(P ′) ≡
EP ′ [EP ′ [f(O)|A = a,W ]], the gradient at P ′ is
o 7→ 1{A = a}
P ′(a|w) {f(o)− EP ′ [f(o)|A,W ]}+ EP ′ [f(o)|A = a,W ]− Φ
f,a(P ′).
The proof concludes by noting that Ψk(P
′) = Φfk,ak(P ′) for all k = 1, 2, 3.
B Estimation when Principal Biomarker is Continuous
We first present several lemmas used to prove Theorem 5 from the main text, which estab-
lishes an asymptotically normal distribution for the estimate of the smoothed parameter.
The proof of these lemmas is deferred until after that of Theorem 5. We then prove Theo-
rem 4 from the main text, which shows that, under some conditions, the smoothed parameter
converges to the true, unsmoothed parameter as the bandwidth shrinks to zero.
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We now present the lemmas used in the above proof of Theorem 5. The first lemma uses
fixed functions w 7→ qˇk(w) and w 7→ pˇik(w). When we invoke this theorem, we will do so at
qˆvk,h and Pˆ (ak|W = ·), where we will do to this conditionally on training sample v so that
we can treat these functions as known.
Lemma A.2. Fix k and functions w 7→ qˇk(w) and w 7→ pˇik(w). The class Gk(qˇk, pˇik) defined
in (A.3) is VC-subgraph (van der Vaart and Wellner, 1996). Furthermore, the VC dimension
of this class does not depend on qˇk, pˇik.
The next lemma is useful for establishing that our estimator ensures that the empirical
mean of the smoothed influence function is zero.
Lemma A.3. Fix k ∈ {1, 2, 3}. Define
Zk,hˆn() ≡
1
n
n∑
i=1
1Ai=ak
Pˆ (Ai|Wi)
[
fk,hˆn(Oi)− exp
{
log qˆ
v(i)
k,hˆn
(Wi) + 
}]
.
If A8, then Zk,hˆn(ˆk) = 0 with probability approaching one.
The final lemma presents a technical condition controlling a class used in the proof of
Theorem 5.
Lemma A.4. Fix δ > 0. Under the conditions of Theorem 5, the class G˜v
k,δ,h¯n
defined in
the proof of Theorem 5 has envelope cδ for a constant c that does not depend on the sample
realization O1, . . . , On.
Proof of Theorem 5. To simplify notation, we assume that n is divisible by 10 so that val-
idation fold v is of size n/10 – note that the results of this proof go through without this
assumption. We let P vn denote the empirical distribution of the observations in validation
set v. For a function g and a distribution Q, we let Qg = EQ[g(O)].
Fix k ∈ {1, 2, 3}. By the same expansion used to establish (5),
Ψk,h(P
′)−Ψk,h(P ) = −PDP ′k,h + Remk,h(P, P ′), (A.1)
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where, with q′k,h(w) ≡ EP ′ [fk,h(O)|ak, w],
Remk,h(P, P
′) = EP
[
(P ′(ak|W )− P (ak|W ))
(
q′k,h(W )− qk,h(W )
)
P ′(ak|W )
]
.
By Cauchy-Schwarz and A8, this remainder upper bounds as
|Remk,h(P, P ′)| ≤ δ−1 ‖P ′(ak|W = ·)− P (ak|W = ·)‖
∥∥q′k,h − qk,h∥∥ .
For a given training fold v, the above is oP (n
−1/2hˆ−1/2n ) by A6 when evaluated at h = hˆn
and P ′ = Pˆ v,∗
k,hˆn
. Multiplying by n−1 and summing the identity (A.1) over v = 1, . . . , 10 and
i ∈ v at h = hˆn and P ′ = Pˆ v,∗k,hˆn , shows that
ψˆk,h −Ψk,h(P ) = − 1
n
10∑
v=1
∑
i:v(i)=1
E
[
D
Pˆ v,∗
k,hˆn
k,hˆn
(O)
]
+ oP (n
−1/2hˆ−1/2n ).
Using Lemma A.3, with probability approaching 1 the above shows that
ψˆk,h −Ψk,h(P ) = 1
10
10∑
v=1
(P vn − P )D
Pˆ v,∗
k,hˆn
k,hˆn
+ oP (n
−1/2hˆ−1/2n ). (A.2)
Consider the following R6-valued data structure, which can be derived from the observed
data structure: O ≡ (qˇk(W ), pˇik(W ), A, S, Sc, Y ). For i = 1, . . . , n, we will let Oi denote
their corresponding R6-valued data structure. Noting that fk,h(o) can be evaluated from
o = (qˇk(w), pˇik(w), a, s, s
c, y), we define f˜k,h so that f˜k,h(o) = fk,h(o). For fixed functions
w 7→ qˇk(w) and w 7→ pˇik, define the class
Gk(qˇk, pˇik) ≡
{
o 7→ gvk,,h(o) :  ∈ R, h ∈ R
}
, (A.3)
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where
gvk,,h(o) ≡
1a=ak
pˇik(w)
[
f˜k,h(o)− exp {log qˇk(w) + }
]
+ exp [log qˇk(w) + ] . (A.4)
Lemma A.2 demonstrates that Gk(qˇk, pˇik) is VC-subgraph (van der Vaart and Wellner, 1996),
and that the VC dimension does not depend on qˇk, pˇik. For each v and for the class
Gk(qˆvk,h, w 7→ Pˆ v(ak|w)), let gvk,,h denote the element of this class indexed by  and h. Note
that (A.2) rewrites as
ψˆk,h −Ψk,h(P ) = 1
10
10∑
v=1
(P vn − P )gvk,ˆk,hˆn + oP (n
−1/2hˆ−1/2n ). (A.5)
Consider the following subclass of Gk(qˆvk,h, w 7→ Pˆ v(ak|w)):
Gvk,δ ≡
{
o 7→ gvk,,h(o) : |− ¯k| ≤ δ, |1− hˆn/h¯n| ≤ δh¯1/2n
}
.
The VC dimension of this subclass is no greater than that of Gk(qˆvk,h, w 7→ Pˆ v(ak|w)) and so
is bounded by a constant that does not depend on the sample. Combining this with the fact
that the VC dimension of this subclass is bounded by a universal constant c1 shows that
the VC dimension of the class G˜v
k,δ,h¯n
≡
{
h¯
1/2
n [gvδ − gvk,¯k,h¯n ] : gvδ ∈ Gvk,δ
}
is also bounded by
a constant that does not rely on the sample. Introducing G˜v
k,δ,h¯n
is useful because, for any
fixed δ > 0, (A.5) combined with A5 and A9 yield that, with probability approaching one,
∣∣∣∣∣ψˆk,h −Ψk,h(P )− 110
10∑
v=1
(P vn − P )gvk,¯k,h¯n − oP (n−1/2hˆ−1/2n )
∣∣∣∣∣
≤
∣∣∣∣∣ 110
10∑
v=1
(P vn − P )(gvk,ˆk,hˆn − g
v
k,¯k,h¯n
)
∣∣∣∣∣ ≤ 110h¯1/2n
10∑
v=1
sup
g˜vδ∈G˜vk,δ,h¯n
|(P vn − P )g˜vδ | . (A.6)
Lemma A.4 shows that the class G˜v
k,δ,h¯n
has an envelope upper bounded by cδ for a constant
c that does not depend on the sample, i.e. supg∈G˜v
k,δ,h¯n
|g(o)| ≤ cδ for all o. Now, for each
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v we know that G˜v
k,δ,h¯n
is a VC-class and there exists an upper bound on the VC-dimension
that does not depend on O1, . . . , On, and so Theorem 2.14.1 in van der Vaart and Wellner
(1996) can be used to show that, conditionally on the training set v,
n1/2 EP v0
 sup
g˜vδ∈G˜vk,δ,h¯n
|(P vn − P )g˜vδ |2
1/2 . δ,
where P v0 is the distribution of the data in validation fold v and here and throughout we
use “.” to denote “less than or equal to up to a positive multiplicative constant that does
not depend on the observations O1, . . . , On”. The above holds for all δ. Therefore, for
any deterministic sequence δn ↓ 0, the above shows that the right-hand side of (A.6) is
oP (n
−1/2h¯−1/2n ) for this choice of δ = δn. Moreover, by A5, oP (n−1/2h¯
−1/2
n ) = oP (n
−1/2hˆ−1/2n ).
We will choose the sequence δn ↓ 0 in such a way that the display in (A.6) at δ = δn
holds with probability approaching one. We show that such a sequence exists as follows. Let
Eδ,n denote the event that (A.6) does not hold. Because, for any fixed δ, the complement of
Eδ,n holds with probability approaching one, we know that there exists a sequence εδ,n ↓ 0
so that P{Eδ,n} ≤ εδ,n for all n. As this is true for all δ, there exists a sequence δn ↓ 0 so
that P{Eδn,n} → 0 as n → ∞. One way to construct such a sequence {δn} is as follows:
first, let n1 = 1; then recursively, for j = 1, 2, . . ., choose δn = 1/2
j for all n = nj +
1, . . . , nj+1, where nj+1 is the smallest natural number that is greater than nj such that
max{ε1/2j ,nj+1 , ε1/2j+1,nj+1} ≤ 1/2j — notably, the fact that max{ε1/2j ,n, ε1/2j+1,n} → 0 as
n → ∞ implies that nj+1 is finite. The event Eδn,n occurs with probability approaching
zero along this deterministic sequence, and so the display in (A.6) holds with probability
approaching one when δ = δn. Plugging this choice of {δn} sequence into the discussion from
the previous paragraph, which controlled the right-hand side of (A.6) for a given sequence
δn ↓ 0, we see that
ψˆk,h −Ψk,h(P ) = 1
10
10∑
v=1
(P vn − P )gvk,¯k,h¯n + oP (n−1/2hˆ−1/2n ).
42
For each v, the function gv
k,¯k,h¯n
does not depend on validation sample v. Therefore, Cheby-
shev’s inequality applied over each (P vn − P )gvk,¯k,h¯n can be used to show that, if there exists
a function gk,¯k,h¯n such that h¯nP
v
0 [(g
v
k,¯k,h¯n
− gk,¯k,h¯n)2] = oP (1), then (P vn −P )gvk,¯k,h¯n is equal
to (P vn − P )gk,¯k,h¯n + oP (n−1/2h¯−1/2n ), where under A5 the oP term can also be expressed as
oP (n
−1/2hˆ−1/2n ). Under A4, the convergence to a fixed function gk,¯k,h¯n does indeed hold, with
gk,¯k,h¯n defined in (8). Hence,
ψˆk,h −Ψk,h(P ) = 1
10
10∑
v=1
(P vn − P )gk,¯k,h¯n + oP (n−1/2hˆ−1/2n )
= (Pn − P )gk,¯k,h¯n + oP (n−1/2hˆ−1/2n ).
The above asymptotically linear expansion holds for each k.
Let g¯,h¯n : o 7→ (gk,¯k,h¯n(o) : k = 1, 2, 3). Using A4 and A8, each component in the
R3-valued vector g¯,h¯n(O) is almost surely bounded by a universal constant times h¯−1n for
O ∼ P . Using that h¯n and hˆn are essentially equivalent under A5, our result will follow
if we establish asymptotic normality of the sequence n1/2(Pn − P )h¯1/2n Σ−1/2n g¯,h¯n . We do
this via a Crame´r-Wold device and a central limit theorem for triangular arrays. Let b be
an R3-valued column vector. Observe that A10 ensures that, with probability approaching
one as n → ∞, h¯1/2n bTΣ−1/2n g¯,h¯n(O) is almost surely bounded by a constant cb times h¯−1/2n .
Furthermore, VarP [h¯
1/2
n Σ
−1/2
n bTg¯,h¯n(O)] is equal to ‖b‖2. Using that nh¯n → ∞ (A5), one
can show that the Lindeberg condition for triangular arrays is satisfied and the sequence
〈b, n1/2(Pn − P )h¯1/2n Σ−1/2n g¯,h¯n〉 converges in distribution to a normal random variable with
variance ‖b‖2. As b was arbitrary, n1/2(Pn−P )h¯1/2n Σ−1/2n g¯,h¯n converges to a N(0, Id) random
variable.
Proof of Lemma A.2. The subgraph of a class G ′ ≡ {o 7→ g(o) : g} is defined as the set
{(o, z) : z < g(o)}. For a pair (o, z), membership to this set can be computed by first
computing g(o), and subsequently returning an indicator that z < g(o). Now, for Gk, these
functions g are indexed only by parameters (, h) ∈ R2. Furthermore, for properly defined
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t that only depends on the choice of kernel K, A7 ensures that all of these these functions
can be computed using no more than a total of t arithmetic operations (+, −, ÷, ×),
indicator functions (x 7→ 1{x > c} for a constant c), and exponential functions (x 7→ ex).
By Theorem 8.14 in Anthony and Bartlett (1999), the VC-dimension of this class is no more
than m(t+ 2)(t+ 2 + 19 log2[9(t+ 2)]), hence is finite and does not depend on qˇk, pˇik.
Proof of Lemma A.3. Fix k ∈ {1, 2, 3}. By the strong positivity assumption, with probabil-
ity approaching one there exists at least one i such that Ai = ak. Without loss of generality,
suppose that this holds. Combining this with the bound on qˆv
k,hˆn
in A8, Zk,hˆn is a mono-
tonically strictly decreasing. Furthermore, Zk,hˆn() respectively diverges to +∞ and −∞
as  tends to −∞ and +∞. Furthermore, Zk,hˆn is continuous, and therefore there exists a
(unique) solution in  to Zk,hˆn() = 0, and this solution must coincide with ˆk, defined as the
minimizer of Zk,hˆn()
2 in .
Proof of Lemma A.4. Note that
h¯1/2n |gvk,,h(o)− gvk,¯k,h¯n(o)|
≤ h¯1/2n
1a=ak
Pˆk(ak|w)
∣∣fk,h(o)− fk,h¯n(o)∣∣+ h¯1/2n
∣∣∣∣∣ 1a=akPˆk(ak|w) − 1
∣∣∣∣∣ ∣∣∣elog qˆvk,h(w)+ − elog qˆvk,h(w)+¯k∣∣∣
≤ h¯1/2n Pˆk(ak|w)−1
[∣∣fk,h(o)− fk,h¯n(o)∣∣+ ∣∣∣elog qˆvk,h(w)+ − elog qˆvk,h(w)+¯k∣∣∣]
By (A7), K is bounded and so
∣∣fk,h(o)− fk,h¯n(o)∣∣ . |h−1 − h¯−1n |. Using a Taylor expansion
and the bound on qˆvk,h from (A8), we also have that, with probability approaching one,∣∣∣elog qˆvk,h(w)+ − elog qˆvk,h(w)+¯k∣∣∣ . |− ¯k|. Furthermore, by (A8), Pˆk(ak|w)−1 . 1. Hence,
|gvk,,h(o)− gvk,¯k,h¯n(o)| . h¯1/2n |h−1 − h¯−1n | − h¯1/2n |− ¯k|
= h¯−1/2n
∣∣∣∣1− hh¯n
∣∣∣∣ (1 + [ h¯nh − 1
])
− h¯1/2n |− ¯k|
If gvk,,h falls in Gvk,δ, then the right-hand side upper bounds by cδ for a constant c that does
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not depend on O1, . . . , On. Therefore, the envelope of the class G˜vk,δ,h¯n is of the order δ.
Proof of Theorem 4. Fix k ∈ {1, 2, 3} and suppose that r ≥ t+ 1. A Taylor series expansion
shows that
Ψk,h(P )−Ψk(P ) =
∫
[Ψk(P ; s)−Ψk(P )]Kh(s− s?1)ds
=
t∑
j=1
[
1
j!
∂j
∂sj
Ψk(P ; s)
∣∣∣∣
s=s?1
∫
(s− s?1)jKh(s− s?1)ds
]
+
∫
(s− s?1)t+1
(t+ 1)!
∂t+1
∂st+1
Ψk(P ; s)
∣∣∣∣
s=s˜s
Kh(s− s?1)ds,
where each s˜s is an intermediate value falling between s and s
?
1. So, the right-hand side is
equal to the final term. By the uniform bound on the (t + 1)th derivative of s 7→ Ψk(P ; s),
the magnitude of the final term is upper bounded by a t-dependent constant times
∫ ∣∣(s− s?1)t+1Kh(s− s?1)∣∣ ds = ht+1 ∫
∣∣∣∣∣
(
s− s?1
h
)t+1
K
(
s− s?1
h
)∣∣∣∣∣ dsh = ht+1
∫ ∣∣ut+1K(u)∣∣ du.
The right-hand side is O(ht+1) by assumption. The result follows because k ∈ {1, 2, 3} was
arbitrary.
C Efficient Influence Functions
We now review the definition of efficient influence functions, which is used in Theorem 2.
Define the following fluctuation submodel through P :
dP(o) ≡ [1 + h(o)] dP (o), where EP [h(O)] = 0 and sup
o
|h(o)| <∞.
The function h is a score, and the closure of the linear span of all scores yields the tan-
gent space. It is the resulting tangent space that is important, as pathwise differentiability
is equivalent for any set of functions h that yield the same tangent space. Hence, the re-
45
striction that supo∈O |h(o)| < ∞, while convenient, will have no impact on the resulting
differentiability properties.
The parameter Ψ is called pathwise differentiable at P if there exists a DP ∈ L20(P ), i.e.
a DP such that DP (O) has mean zero and finite variance under O ∼ P , such that
Ψ(P)−Ψ(P ) = 
∫
DP (o)h(o)dP (o) + o().
We call DP a gradient of Ψ at P . The efficient influence function is the gradient DP for
which DP (O), O ∼ P , has minimal variance. In a nonparametric model, DP (O) is almost
surely unique.
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D Two-Phase Sampling Algorithms
Algorithm 3 TMLE for Estimating Ψ1(P ), Ψ2(P ), and Ψ3(P ) under Two-Phase Sampling
Takes as input n observations Obs ≡ {Oi : i = 1, . . . , n}, and also the weights ∆ipi−1i .
function TMLE(Obs)
Stabilization: For a = 0, 1, let c(a) ≡
∑
i:Ai=a
∆i/pii
#{i:Ai=a} . For each i, let p¯ii ≡ c(Ai)pii.
. For a = 0, 1, the choice of c(a) ensures that 1
#{i:Ai=a}
∑
i:Ai=a
∆ip¯i
−1
i = 1.
Initial Estimates: Define an initial estimator Pˆ of P :
• The marginal distribution of W under Pˆ should be the weighted empirical dis-
tribution, for which each observations puts a mass of ∆ip¯i
−1
i at each observation
O˜i.
• Only the estimates of the components of P (O|W ) needed to evaluate Ψk and Dk,
k = 1, 2, 3, are needed: Pˆ (A = 1|W = ·), Pˆ (Y = 1|S = s?1, A = 1,W = ·),
Pˆ (S = s?1|A = 1,W = ·), and Pˆ (Y = 0, Sc = s?1|A = 0,W = ·).
. If estimated using loss-based learning, include observation weights ∆ip¯i
−1
i .
for k = 1, 2, 3 do . Recall the definitions of fk and ak from Theorem 2.
Fluctuation for Targeting Step: Using observations i = 1, . . . , n, fit the in-
tercept ˆk using an intercept-only logistic regression with outcome fk(Oi), offset
logit Pˆ {fk(O) = 1|a, w}, and weights 1Ai=akPˆ (Ai|Wi)∆ip¯i
−1
i .
Targeting Step: We now define a fluctuation of Pˆ ∗k of Pˆ , targeted towards esti-
mation of ψk. Define
Pˆ ∗k {fk(O) = 1|ak, w} ≡ expit
{
logit Pˆ {fk(O) = 1|ak, w}+ ˆk
}
.
The marginal distribution of W ∼ Pˆ does not need to be fluctuated.
Plug-In Estimator: The estimator of ψk is ψˆk ≡ Ψk(Pˆ ∗k ), and the estimate of the
corresponding component of the (full data) influence function is Dˆk ≡ DPˆ
∗
k
k .
. Here, by “full data” influence function, we mean that Dˆk is the influence function
that we would have had if the phase two covariates had been measured on all sub-
jects. When subsequently developing confidence intervals, Dˆk(Oi) will be weighted
by ∆ip¯i
−1
i .
return Estimate ψˆ ≡ (ψˆk : k = 1, 2, 3) and estimated full data influence function
Dˆ ≡ (Dˆk : k = 1, 2, 3).
E Additional Simulation Results
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s∗1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
Bias, Truth 0.03 0.04 0.04 0.03 0.03 0.03 0.03 0.05 0.06 0.08
Bias, Smoothed 0.04 0.05 0.02 -0.01 -0.01 0.02 0.05 0.08 0.07 0.06
Standard Error 0.28 0.27 0.26 0.26 0.27 0.29 0.31 0.34 0.39 0.49
Coverage, Truth 0.97 0.97 0.98 0.98 0.97 0.97 0.97 0.97 0.97 0.96
Coverage, Smoothed 0.97 0.97 0.97 0.96 0.96 0.97 0.97 0.98 0.97 0.96
Table 2: Bias, standard error, and coverage probability of the log relative risk point estimator
and confidence intervals for different s∗1 values with bandwidth chosen to be h = 0.1.
s∗1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
Bias, Truth -0.03 -0.02 0.00 0.02 0.04 0.06 0.08 0.10 0.13 0.15
Bias, Smoothed 0.03 0.02 0.02 0.02 0.01 0.01 0.00 -0.00 -0.00 0.00
Standard Error 0.14 0.13 0.13 0.13 0.13 0.14 0.14 0.15 0.17 0.19
Coverage, Truth 0.93 0.94 0.94 0.95 0.95 0.94 0.93 0.93 0.92 0.92
Coverage, Smoothed 0.96 0.95 0.94 0.95 0.95 0.95 0.96 0.96 0.95 0.95
Table 3: Bias, standard error, and coverage probability of the log relative risk point estimator
and confidence intervals for different s∗1 values with bandwidth chosen to be h = 0.3.
s∗1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
Bias, Truth -0.07 -0.04 -0.01 0.02 0.05 0.08 0.12 0.15 0.18 0.22
Bias, Smoothed 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.00 -0.00
Standard Error 0.11 0.11 0.11 0.11 0.11 0.11 0.12 0.13 0.14 0.15
Coverage, Truth 0.90 0.93 0.95 0.95 0.93 0.91 0.84 0.79 0.73 0.71
Coverage, Smoothed 0.95 0.96 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.96
Table 4: Bias, standard error, and coverage probability of the log relative risk point estimator
and confidence intervals for different s∗1 values with bandwidth chosen to be h = 0.4.
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